Trials / Completed
CompletedNCT00893971
Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects
A Randomized, Double-blind, Single Dose, Four-period, Four-treatment, Cross-over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Pearl Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety of a single dose of PT003 compared with single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as two separate single doses in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PT001 | Inhaled PT001, single dose |
| DRUG | PT005 | Inhaled PT005, single dose |
| DRUG | PT003 | Inhaled PT003, single dose |
| DRUG | PT001 + PT005 | Inhaled PT001 + PT005, single dose |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2009-05-06
- Last updated
- 2017-04-26
- Results posted
- 2017-04-26
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00893971. Inclusion in this directory is not an endorsement.